依维莫司联合芳香化酶抑制剂一线化疗后维持治疗:MAIN-A III期试验最终结果
MAIN-A研究是一项III期随机试验,纳入一线化疗后疾病控制的HR+/HER2-转移性乳腺癌患者,比较依维莫司联合芳香化酶抑制剂(AI)与AI单药维持治疗。两组中位PFS分别为11.0个月和7.2个月(HR 0.71,95%CI 0.47-1.06),中位OS分别为35.7个月和33.5个月(HR 1.0,95%CI 0.61-1.62)。联合治疗未显著改善结局,维持内分泌治疗仍为标准。
要点
- 依维莫司联合AI较AI单药未显著改善PFS(HR 0.71,95%CI 0.47-1.06)。
- 联合组与单药组中位OS分别为35.7个月和33.5个月(HR 1.0)。
- 考虑耐受性,维持内分泌治疗仍为标准方案。
核心结论
- 依维莫司联合芳香化酶抑制剂未显著改善适合一线化疗的转移性乳腺癌患者结局。
- 考虑治疗耐受性,维持内分泌治疗仍为标准。
研究设计与样本
- 随机III期试验,纳入一线化疗后达疾病控制(稳定、部分缓解或完全缓解)的HR+/HER2-转移性乳腺癌患者。
- 共110例患者随机至依维莫司联合AI组(n=52)或AI单药组(n=58)。
- 主要终点为无进展生存期(PFS),次要终点包括缓解率、安全性和总生存期(OS)。
主要发现
- 依维莫司联合AI组中位PFS为11.0个月(95%CI 8.1-13.8),AI单药组为7.2个月(95%CI 4.7-10.9),HR 0.71(95%CI 0.47-1.06)。
- 联合组客观缓解率为22.4%,单药组为19.2%。
- AI单药组以疾病进展为最佳缓解的比例更高(28.8% vs 14.3%)。
- 联合组中位OS为35.7个月(95%CI 26.0-47.8),单药组为33.5个月(95%CI 26.4-42.7),HR 1.0(95%CI 0.61-1.62)。
临床怎么用
- 对于一线化疗后疾病控制的HR+/HER2-转移性乳腺癌患者,维持内分泌治疗仍为标准。
- 不推荐常规添加依维莫司用于维持治疗,需考虑治疗耐受性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite endocrine therapy being the mainstay of treatment for hormone receptor positive (HR+)/HER2- metastatic breast cancer, patients at risk of visceral crisis or doubt for endocrine sensitivity are still offered first-line chemotherapy. Maintenance hormonal therapy is generally offered at the discontinuation of chemotherapy. The MAINtenance Afinitor study is a randomised, phase III trial comparing maintenance everolimus combined with aromatase inhibitors (AIs) versus AI monotherapy in patients with disease control after first-line chemotherapy. METHODS: Patients with stable disease, partial response or complete response after first-line chemotherapy were randomised to everolimus plus AIs (exemestane or letrozole or anastrozole) or to AIs alone. Primary aim was progression-free survival (PFS). Secondary aims included response rate, safety and overall survival (OS). RESULTS: In total, 110 patients were randomised to everolimus + AIs (n = 52) or to AIs (n = 58). Median PFS was 11.0 months (95% confidence interval [CI] 8.1-13.8) in the everolimus + AI arm and 7.2 months (95% CI 4.7-10.9) in the AI monotherapy arm (hazard ratio [HR] 0.71, 95% CI 0.47-1.06). Objective response rate was 22.4% in everolimus + AI arm and 19.2% in AI monotherapy arm. A higher proportion of disease progression as best response was reported in the AI monotherapy arm (28.8% versus 14.3%). Median OS was 35.7 months (95% CI 26.0-47.8) in the combination arm versus 33.5 (95% CI 26.4-42.7) in the AI alone arm (HR 1.0, 95% CI 0.61-1.62). CONCLUSIONS: EVE + AIs did not significantly impact on the outcome of metastatic breast cancer patients deemed suitable for first-line chemotherapy. Also taking into account treatment tolerability, maintenance endocrine therapy remains the standard. TRIAL REGISTRATION: EudraCT: 2013-004153-24.
引用
- Guarneri V, Giorgi CA, Cinieri S, et al. Everolimus plus aromatase inhibitors as maintenance therapy after first-line chemotherapy: Final results of the phase III randomised MAIN-A (MAINtenance Afinitor) trial. Eur J Cancer. 2021. PMID: 34225066. doi:10.1016/j.ejca.2021.05.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。